Shantel Weinsheimer

Shantel Weinsheimer

Auto-generated profile, based on publicly available information

Shantel Weinsheimer

Department of Anesthesia and Perioperative Care, Center for Cerebrovascular Research University of California San Francisco CA, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2022 in Science
Verified
Journal Article
Closed access
EWEthan A. Winkler
Ethan A. Winkler
CKChang N. Kim
Chang N. Kim
JRJayden M. Ross
Jayden M. Ross
JGJoseph H. Garcia
Joseph H. Garcia
EGEugene Gil
Eugene Gil
TNTomasz Jan Nowakowski
Tomasz Jan Nowakowski
Cerebrovascular diseases are a leading cause of death and neurologic disability. Further understanding of disease mechanisms and therapeutic strategies requires a deeper knowledge of cerebrovascular cells in humans. We profiled transcriptomes of 181,388 cells to define a cell atlas of the adult human cerebrovasculature, including endothelial cell molecular signatures with arteriovenous segmentation and expanded perivascular cell diversity. By leveraging this reference, we investigated cellular and molecular perturbations in brain arteriovenous malformations, which are a leading cause of stroke in young people, and identified pathologic endothelial transformations with abnormal vascular patterning and the ontology of vascularly derived inflammation. We illustrate the interplay between vascular and immune cells that contributes to brain hemorrhage and catalog opportunities for targeting angiogenic and inflammatory programs in vascular malformations.

29 August 2017 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
ASAnna Starnawska
Anna Starnawska
CHC S Hansen
C S Hansen
TST Sparsø
T Sparsø
WMW Mazin
W Mazin
LOL Olsen
L Olsen
SWS Weinsheimer
S Weinsheimer
Individuals with 22q11.2 deletion syndrome (DS) have an increased risk of comorbid mental disorders including schizophrenia, attention deficit hyperactivity disorder, depression, as well as intellectual disability. Although most 22q11.2 deletion carriers have the long 3-Mb form of the hemizygous deletion, there remains a large variation in the development and progression of psychiatric disorders, which suggests that alternative factors contribute to the pathogenesis. In this study we investigated whether neonatal DNA methylation signatures in individuals with the 22q11.2 deletion associate with mental disorder later in life. DNA methylation was measured genome-wide from neonatal dried blood spots in a cohort of 164 individuals with 22q11.2DS, including 48 individuals diagnosed with a psychiatric disorder. Among several CpG sites withP-value<10−6, we identified cg23546855 (P-value=2.15 × 10−7) mapping toSTK32Cto be associated with a later psychiatric diagnosis. Pathway analysis of the top findings resulted in the identification of several Gene Ontology pathways to be significantly enriched (P-value<0.05 after Benjamini–Hochberg correction); among them are the following: neurogenesis, neuron development, neuron projection development, astrocyte development, axonogenesis and axon guidance. In addition, we identified differentially methylated CpG sites inLRP2BP(P-value=5.37 × 10−8) to be associated with intellectual disability (F70–79), inTOP1(P-value=1.86 × 10−7) with behavioral disorders (F90–98), inNOSIP(P-value=5.12 × 10−8) with disorders of psychological development (F80–89) and inSEMA4B(P-value=4.02 × 10−7) with schizophrenia spectrum disorders (F20–29). In conclusion, our study suggests an association of DNA methylation differences at birth with development of mental disorder later in life in 22q11.2DS individuals.

1 June 2024 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
EFEduardo Frias-Anaya
Eduardo Frias-Anaya
HGHELIOS GALLEGO-GUTIERREZ
HELIOS GALLEGO-GUTIERREZ
BGBrendan Gongol
Brendan Gongol
SWShantel Weinsheimer
Shantel Weinsheimer
CLCatherine Chinhchu Lai
Catherine Chinhchu Lai
MLMiguel Alejandro Lopez-Ramirez
Miguel Alejandro Lopez-Ramirez
BACKGROUND: Heterogeneity in the severity of cerebral cavernous malformations (CCMs) disease, including brain bleedings and thrombosis that cause neurological disabilities in patients, suggests that environmental, genetic, or biological factors act as disease modifiers. Still, the underlying mechanisms are not entirely understood. Here, we report that mild hypoxia accelerates CCM disease by promoting angiogenesis, neuroinflammation, and vascular thrombosis in the brains of CCM mouse models. METHODS: We used genetic studies, RNA sequencing, spatial transcriptome, micro–computed tomography, fluorescence-activated cell sorting, multiplex immunofluorescence, coculture studies, and imaging techniques to reveal that sustained mild hypoxia via the CX3CR1-CX3CL1 (CX3C motif chemokine receptor 1/chemokine [CX3C motif] ligand 1) signaling pathway influences cell-specific neuroinflammatory interactions, contributing to heterogeneity in CCM severity. RESULTS: Histological and expression profiles of CCM neurovascular lesions ( Slco1c1-iCreERT2;Pdcd10 fl/fl ; Pdcd10 BECKO ) in male and female mice found that sustained mild hypoxia (12% O 2 , 7 days) accelerates CCM disease. Our findings indicate that a small reduction in oxygen levels can significantly increase angiogenesis, neuroinflammation, and thrombosis in CCM disease by enhancing the interactions between endothelium, astrocytes, and immune cells. Our study indicates that the interactions between CX3CR1 and CX3CL1 are crucial in the maturation of CCM lesions and propensity to CCM immunothrombosis. In particular, this pathway regulates the recruitment and activation of microglia and other immune cells in CCM lesions, which leads to lesion growth and thrombosis. We found that human CX3CR1 variants are linked to lower lesion burden in familial CCMs, proving it is a genetic modifier in human disease and a potential marker for aggressiveness. Moreover, monoclonal blocking antibody against CX3CL1 or reducing 1 copy of the Cx3cr1 gene significantly reduces hypoxia-induced CCM immunothrombosis. CONCLUSIONS: Our study reveals that interactions between CX3CR1 and CX3CL1 can modify CCM neuropathology when lesions are accelerated by environmental hypoxia. Moreover, a hypoxic environment or hypoxia signaling caused by CCM disease influences the balance between neuroinflammation and neuroprotection mediated by CX3CR1-CX3CL1 signaling. These results establish CX3CR1 as a genetic marker for patient stratification and a potential predictor of CCM aggressiveness.

21 July 2014 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
PKP H C Kremer
P H C Kremer
BKB P C Koeleman
B P C Koeleman
LPL Pawlikowska
L Pawlikowska
SWS Weinsheimer
S Weinsheimer
NBN Bendjilali
N Bendjilali
CKC J M Klijn
C J M Klijn
Background In genome-wide association studies (GWAS) five putative risk loci are associated with intracranial aneurysm. As brain arteriovenous malformations (AVM) and intracranial aneurysms are both intracranial vascular diseases and AVMs often have associated aneurysms, we investigated whether these loci are also associated with sporadic brain AVM. Methods We included 506 patients (168 Dutch, 338 American) and 1548 controls, all Caucasians. Controls had been recruited as part of previous GWAS. Dutch patients were genotyped by KASPar assay and US patients by Affymetrix SNP 6.0 array. Associations in each cohort were tested by univariable logistic regression modelling, with subgroup analysis in 205 American cases with aneurysm data. Meta-analysis was performed by a Mantel-Haenszel fixed-effect method. Results In the Dutch cohort none of the single nucleotide polymorphisms (SNPs) were associated with AVMs. In the American cohort, genotyped SNPs near SOX-17 (OR 0.74; 95% CI 0.56–0.98), RBBP8 (OR 0.76; 95% CI 0.62–0.94) and an imputed SNP near CDKN2B-AS1 (OR 0.79; 95% CI 0.64–0.98) were significantly associated with AVM. The association with SNPs near SOX-17 and CDKN2B-AS1 but not RBBP8 were strongest in patients with AVM with associated aneurysms. In the meta-analysis we found no significant associations between allele frequencies and AVM occurrence, but rs9298506, near SOX-17 approached statistical significance (OR 0.77; 95% CI 0.57–1.03, p=0.08). Conclusions Our meta-analysis of two Caucasian cohorts did not show an association between five aneurysm-associated loci and sporadic brain AVM. Possible involvement of SOX-17 and RBBP8, genes involved in cell cycle progression, deserves further investigation.

1 January 2024 in Cells
Verified
Journal Article
Open access
PDF file
ZSZahra Shabani
Zahra Shabani
JSJoana Schuerger
Joana Schuerger
XZXiaonan Zhu
Xiaonan Zhu
CTChaoliang Tang
Chaoliang Tang
LMLi Ma
Li Ma
Hua SuHua Su
Hua Su
Background: The increase in the collagen I (COL I)/COL III ratio enhances vessel wall stiffness and renders vessels less resistant to blood flow and pressure changes. Activated microglia enhance inflammation-induced fibrosis. Hypotheses: The COL I/COL III ratio in human and mouse brain arteriovenous malformations (bAVMs) is associated with bAVM hemorrhage, and the depletion of microglia decreases the COL I/COL III ratio and hemorrhage. Method: COL I, COL III, and hemorrhages were analyzed in 12 human bAVMs and 6 control brains, and mouse bAVMs induced in three mouse lines with activin receptor-like kinase 1 (n = 7) or endoglin (n = 7) deleted in the endothelial cells or brain focally (n = 5). The controls for the mouse study were no-gene-deleted litter mates. Mouse bAVMs were used to test the relationships between the Col I/Col III ratio and hemorrhage and whether the transient depletion of microglia reduces the Col I/Col III ratio and hemorrhage. Results: The COL I/COL III ratio was higher in the human and mouse bAVMs than in controls. The microhemorrhage in mouse bAVMs was positively correlated with the Col I/Col III ratio. Transient depletion of microglia reduced the Col I/Col III ratio and microhemorrhage. Conclusions: The COL I/COL III ratio in the bAVMs was associated with bAVM hemorrhage. The depletion of microglia reduced the bAVM Col I/Col III ratio and hemorrhage.

2 August 2025 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
JKJanne Koskimäki
Janne Koskimäki
AJAditya Jhaveri
Aditya Jhaveri
ASAbhinav Srinath
Abhinav Srinath
ABAkash Bindal
Akash Bindal
DCDiana Vera Cruz
Diana Vera Cruz
IAIssam A. Awad
Issam A. Awad
Familial cerebral cavernous malformations (FCCM), Sturge-Weber Syndrome (SWS), and hereditary hemorrhagic telangiectasia (HHT) are driven by genetic mutations causing varying vascular dysmorphism and risk of brain bleeding. Cerebral microbleeds (CMBs) are associated with the aging process with less characterized genetic drivers. This study hypothesizes that common and distinct circulating microRNAs (miRNAs) can reflect mechanisms of vascular dysmorphism and bleeding, which can serve as potential biomarkers in clinical contexts. Differentially expressed (DE) plasma miRNAs (p < 0.05, FDR corrected, absolute fold change [|FC|]>1.5]) were identified between patients with FCCM, SWS, HHT, and CMB, compared to age and sex matched healthy patients. Ingenuity Pathway Analysis as well as transcriptome integration analyses were performed to identify gene targets of the DE miRNAs and their associated pathways. Preselected miRNAs were validated using ddPCR. Eleven circulating DE miRNAs were identified in FCCM, 40 in SWS, 41 in HHT, and 26 in CMB (p < 0.05, FDR-corrected, [|FC|]>1.5]). Further analyses showed that 18 DE miRNAs were commonly dysregulated in any two of the studied neurovascular disorders. The PI3K-Akt and ROBO SLIT signaling pathways were identified across all four disorders. The plasma levels of four miRNAs were further validated (p < 0.05) using ddPCR. The common dysregulated miRNAs across neurovascular disorders reflect shared mechanistic pathways underlying vascular dysmorphism and bleeding. These findings pave the way for further mechanistic exploration of these miRNAs, and their potential clinical application for disease monitoring and therapeutic intervention.